Palbociclib in combination with TDM1 for metastatic HER2+ breast cancer

  • Knudsen E
  • Frankel A
  • Chang J
  • et al.
N/ACitations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: HER2+ breast cancer is treated using agents that target the amplified receptor. Such drugs are effective; however, recurrence and progression can occur in spite of multiple HER2-targeted therapies. This study evaluated the safety and potential efficacy of the combination of TDM-1 and palbociclib in previously treated metastatic HER2+ breast cancer. Background: Preclinical data indicate that the CDK4/6 inhibition suppresses proliferation of HER2+ tumor models, including those resistant to HER2-targeted therapies. The action of CDK4/6 inhibitors is distinct from HER2-targeted agents. In particuar TDM1 elicits a cytotoxic response; while CDK4/6 inhibition prevents outgrowth of tumors that survive T-DM1. These data were used to develop scheduling for a study to evaluate the safety and preliminary efficacy of palbociclib combined with TDM-1 in advanced HER2+ breast cancer. Experimental design: A standard 3X3 design Phase I trial design was applied. Centrally confirmed HER2+ and RB-intact advanced breast cancer patients, including those previously exposed to TDM-1, were enrolled. Patients received TDM-1 (3.6 mg/kg) IV every 21 days and palbociclib orally on days 5-18 of each cycle. Dose escalation occurred in 100, 150 and 200 mg cohorts. Of 18 patients screened, two were excluded due to lack of HER2-positivity or observed RB-deficiency. Nine patients were in the dose escalation and 44% (4/9) had received prior TDM-1 therapy. Results: Predominant study drug related toxicities were hematologic, with 33% of patients experiencing grade 3 thrombocytopenia. Grade 3 neutropenia related to palbociclib was seen in 33% of patients at 100 mg, 66% at 150 mg, and 100% at 200 mg dose level. Toxicity resolved with dose interruption. Best observed responses included 3 partial responses, 5 stable diseases, and 1 progressive disease. Median cycles was 8, with average time on study 193 days. Of four patients previously relapsing on TDM-1, two had stable disease and one partial response. Conclusions: The TDM-1 and palbocicilb combination was well tolerated with reversible hematologic toxicity and evidence of clinical efficacy. The recommended dose for further study is TDM-1 (3.6 mg/kg) day 1, with 150 mg of palbociclib on days 5-18 of a 21 day cycle.

Cite

CITATION STYLE

APA

Knudsen, E. S., Frankel, A., Chang, J., Witkiewicz, A., & Haley, B. (2017). Palbociclib in combination with TDM1 for metastatic HER2+ breast cancer. Annals of Oncology, 28, i7. https://doi.org/10.1093/annonc/mdx137.002

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free